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E-mail address: hariccb@rediffmail.com (V. V. SureThe synthesis of a new class of 1,2,4-oxadiazole-linked orthogonally urethane-protected dipeptide
mimetics is described. The protocol employs a reaction between an N-protected amino acyl ﬂuoride
and an amino acid-derived amidoxime. All the three commonly employed urethanes have been used
in this protocol for N-protection. The course of the reaction was found to be high yielding and all new
compounds were well characterized by NMR and mass spectroscopy. The O-acyl amidoxime intermediate
has also been isolated as a stable solid.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Peptidomimetics1 are being explored largely to circumvent
some of the disadvantages of native peptides and to increase the
bioavailability and potency of peptide-based drugs.2 Several types
of non-natural linkages such as retro-amides, ureas,3 carbamates,4
sulfonamides,5 thiazoles and6 triazoles,7,8 are used as amide bond
replacements to obtain new classes of peptidomimetics with
considerable success. 1,2,4-Oxadiazoles9 are important amongst
biologically active heterocycles, the utility of which has been
extended to many potent classes of drug-related molecules such
as ligands of benzodiazepine receptors,10 muscuranic receptor ago-
nists,11 antiviral compounds, angiotensin II receptor antagonists12
and HIV-1 reverse transcriptase inhibitors.13 In peptide chemistry,
this group has been studied mainly as an efﬁcient amide and ester
bond bioisoester.14,15
The development of a reliable method for the insertion of 1,2,4-
oxadiazole into peptides ﬁnds utility in the synthesis of large
libraries of small peptide segments for their biological and
therapeutical scrutiny. The general synthesis of 1,2,4-oxadiazoles
involves coupling of an amidoxime with an activated carboxyl
group, yielding an O-acyl amidoxime followed by its dehydrative
cyclization.16 The cyclization of O-acyl amidoximes has been
carried out employing exhaustive reﬂux conditions in DMF or pyr-
idine with or without additives such as 1-[3-(dimethylamino)pro-
pyl]-3-ethylcarbodiimide (EDC), dicyclohexylcarbodiimide (DCC),ll rights reserved.
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shbabu).1,10-carbonyldiimidazole (CDI), O-(benzotriazol-1-yl) N,N,N0,N0-
tetramethyluronium tetraﬂuoroborate (TBTU) and the Burgess
reagent.17 The use of a strong base such as NaOEt or tetrabutyl-
ammonium ﬂuoride (TBAF) allows completion of the reaction even
at rt.18 1,2,4-Oxadiazoles have been incorporated in the synthesis
of a Phe-Gly segment mimetic in the biologically active peptides
such as dermorphin, and in substance P.19 A new variety of 1,2,4-
oxadiazole-linked peptidomimetics have been reported via reac-
tion of Boc-amino acid-derived amidoximes with succinic/glutaric
acid anhydrides in DMF at reﬂux.15 Similar chemistry was explored
also for the synthesis of 1,2,4-oxadiazole-containing b3-amino
acids.20 In one report, a solid-phase methodology was employed
wherein Fmoc/Boc amino acid anhydrides were reacted with
resin-bound amidoximes followed by cyclization.21 The Buchanan
group described a reaction between a Boc amino acid succinimidyl
ester and simple amidoximes with the aid of EDCHOBt followed by
cyclization in reﬂuxing pyridine to obtain the corresponding 1,2,4-
oxadiazole.22 To the best of our knowledge, the synthesis of 1,2,4-
oxadiazole-linked orthogonally protected dipeptide mimetics,
which serve as building blocks for preparation of the correspond-
ing oligopeptide mimetics, is yet to be reported. In the present
work, the synthesis of 1,2,4-oxadiazole-linked N,N0-orthogonally
protected dipeptide mimetics by coupling of an N-protected amino
acid-derived amidoxime with another orthogonally protected ami-
no acid ﬂuoride followed by cyclization is described.
The essential intermediate in the preparation of the 1,2,4-
oxadiazole is an amidoxime, which in the present study was
prepared from the corresponding amino acid-derived nitrile.
Initially, Boc-protected alanyl nitrile, obtained by the dehydration
5134 V. V. Sureshbabu et al. / Tetrahedron Letters 49 (2008) 5133–5136of Boc-Ala-NH2 using triﬂuoroacetic anhydride (TFAA)/TEA, was re-
ﬂuxed in ethanol along with hydroxylammonium chloride
(NH2OHHCl) and solid K2CO3 for 2 h (Scheme 1). The insoluble
inorganics were ﬁltered off, and the ﬁltrate was concentrated to
obtain amidoxime 1 as a stable solid. The generality of this reaction
was demonstrated by the synthesis of a series of amidoximes. Or-
ganic bases such as triethyl amine (TEA) and pyridine were avoided
in order to circumvent racemization. The use of powdered K2CO3
facilitated simpler isolation of the product in good yield and purity.
This procedure was applied to several other Boc/Z-amino acid
nitriles, and the corresponding amidoximes were isolated in
satisfactory yields. However, use of the Fmoc group for amine
protection resulted in a lower yield of the amidoxime due to its
deprotection under the basic reaction conditions. The use of bases
including TEA, pyridine, NaOEt and TBAF did not result in any
improvement of the product yield.
The N-urethane-protected amino acid ﬂuorides23,24 are well
known as stable and useful acylating agents for racemization-free
peptide coupling reactions. Unlike their acid chloride counterparts,
acid ﬂuorides are accessible to all three types of protecting groups,
such as Fmoc, Z and Boc. Also, amongst various ﬂuorinating
reagents, Deoxo-Fluor25,26 is gaining considerable interest for its
fast and efﬁcient reactivity in the preparation of acid ﬂuorides.
Upon treatment of an N-protected amino acid with Deoxo-Fluor
in the presence of N-methylmorpholine (NMM) for 30 min, the cor-
responding acyl ﬂuoride was isolated after a simple workup and
recrystallization/precipitation. All the N-protected amino acyl ﬂu-
orides prepared in this fashion were isolated as stable compounds.
For assembly of the title molecules, the N-protected amino acyl
ﬂuoride 2 was coupled to amino acid-derived amidoxime 1. In a
typical experiment, Boc-Gly-F was stirred with the amidoxime de-
rived from Z-Ile-OH in the presence of NMM in ethanol. AfterPg1-NH CN
R1
NH2OH. HCl
K2CO3, EtOH Pg
1-NH
NH2
R1
N
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, 2 h, 80-90%
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Table 1
1,2,4-Oxadiazole-linked dipeptide mimetics
Compd. Pg1 R1 Pg2 R2
3a Boc CH2CH(CH3)2 Z CH(
3b Boc CH2C6H5 Fmoc CH2
3c Boc H Z CH(
3d Boc CH3 Fmoc CH2
3e Z CH(CH3)CH2CH3 Boc H
3f Z CH2CH(CH3)2 Fmoc CH2
3g Z CH2C6H5 Boc CH2
3h Z CH2C6H5 Fmoc C6H
3i Fmoc CH2CH(CH3)2 Boc CH315 min, an equimolar quantity of sodium acetate was added and
the reaction mixture was reﬂuxed for 3 h. The resulting 1,2,4-
oxadiazolyl dipeptide 3 was isolated after a simple workup
followed by column chromatography as a pure solid in a yield
exceeding 60% (Scheme 2). Several examples of 1,2,4-oxadiazole-
containing dipeptide mimetics possessing different urethanes at
the amino terminal were prepared, and consistently yields and
purities were observed in all cases (Table 1).
When the reaction was repeated without sodium acetate, the
product 1,2,4-oxadiazole was isolated in low yield (<20%) even
after reﬂuxing for more than 6 h. The structures of all the synthe-
sized 1,2,4-oxadiazolyl dipeptide mimetics 3 were conﬁrmed
through NMR and mass spectroscopy. Also the course of the reac-
tion was proved to be racemization-free as was evident by HPLC
analysis.
The protocol was extended by employing peptidyl counterparts
of acyl ﬂuoride and amidoxime units to prepare several 1,2,4-oxa-
diazole-linked tetrapeptides. The peptidyl amidoximes were pre-
pared starting from the N-protected peptide acids in the same
manner as described for 1. They were isolated as stable solids in
good yields, which were found to be enantiomerically pure as ana-
lyzed by HPLC. In a typical example, Z-Val-Gly-OH derived amidox-
ime 4a was reacted with Fmoc-Ala-Phe-F 5a (prepared by treating
the peptide acid with Deoxo-Fluor) in the presence of sodium ace-
tate in reﬂuxing ethanol to afford the corresponding 1,2,4-oxadiaz-
olyl tetrapeptide 6a after 4 h. The material was isolated after a
simple workup and column chromatography as a gum, which
solidiﬁed slowly (Scheme 3).
The oxadiazole formation is a two-step process involving the
formation of O-acyl amidoxime intermediate 7 followed by its
cyclization. Consequently, we turned our interest to the isolation
and characterization of 7. Initially, Z-Val-F was added to a solution
of Boc-Leu-OH derived amidoxime in ethanol followed by NMM at
rt. After complete consumption of the acid ﬂuoride (TLC), the reac-
tion mixture was evaporated without heating and the residue was
washed with water and hexane to afford the O-acyl amidoxime 7
as a stable solid (Scheme 4). Similarly, the reaction was repeated
with a few other combinations of Fmoc/Boc/Z-amino acids and
all the corresponding dipeptidyl O-acyl amidoximes 7 were
obtained in satisfactory yields and purities (Table 2). Notably, the
isolated O-acyl amidoxime, when subjected to cyclization in the
presence of sodium acetate, gave slightly higher yields (>80%) ofMM, Ethanol, 
 15 min
aOAc,
Pg1-NH
N
R1
N O
NH-Pg2
R2
3
2.
Yield (%) Mp (C) ½a25D (c 1, DMF)
CH3)2 65 102 27.14
C6H5 70 112 31.36
CH3)CH2CH3 76 98 26.80
OCH2C6H5 68 114 21.84
71 101 27.65
C6H5 73 116 36.26
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Table 2
List of O-acyl amidoxime intermediates
Product Amidoxime Acyl ﬂuoride Yield
(%)
½a25D
(c 1, DMF)
Pg1 Amino acid Pg2 Amino acid
7a Boc Leu Z Val 72 17.88
7b Z Ile Boc Gly 76 18.56
7c Z Ala Fmoc Phe 73 14.26
7d Boc Phe Fmoc Phe 79 13.50
7e Z Gly Boc Asp(OBz) 70 12.74
Amidoxime 4 Acyl fluoride 5 Yield 
(%)
6a Z-Val-Gly Fmoc-Ala-Phe 57 
6b Boc-Phe-Ala Z-Leu-Gly 73 
6c Fmoc-Val-Met Boc-Ala-Ile 52 
6d Boc-Ala-Leu Z-Phe-Gly 71 
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intermediate (Scheme 5).
Finally, the orthogonality of the urethanes employed to protect
the amino groups in the title compounds 3 was utilized for selec-
tive deprotection and peptide chain extension on either side. In a
case study, 3a was treated with triﬂuoroacetic acid (TFA) in CH2Cl2
to remove the Boc group. The free amino oxadiazole was reacted
with Boc-Phe-F in the presence of TEA and the resulting peptide
was isolated after a simple workup. Similarly, the procedure was
repeated to couple Boc-Val-F to obtain another tripeptidomimetic
molecule. Finally, 1,2,4-oxadiazole 3a was subjected to catalytic
hydrogenation using Pd-C/H2 to deprotect the Z group. The result-
ing free amine was utilized for chain extension by coupling with
Z-Ile-F or Z-Gly-F in presence of TEA. All the peptides were isolated
in good yields (>70%).Boc -Xaa-NH
N
N O
HN-Z
3a1. TFA/CH2Cl2
2. Boc-Xaa-F, 
 NMM
8
8a: Xaa=Phe (74%)
8b: Xaa=Val (75%)
SchemeIn summary, we have developed a simple preparation of 1,2,4-
oxadiazole-linked N,N0-orthogonally protected dipeptidomimetics
by coupling the N-protected amino acid with another N-protected
amino acid-derived amidoxime utilizing an acid ﬂuoride group as
the coupling agent. The resulting dipeptidomimetic building blocks
were utilized for the preparation of 1,2,4-oxadiazole-linked oligo-
peptides through chain extension on either N-terminal.
2. General procedure for N-protected amino acid-derived
amidoxime 1
To a solution of N-protected amino acid nitrile (10 mmol) in
ethanol were added NH2OHHCl (13 mmol) and powdered K2CO3
(13 mmol), and the reaction mixture was reﬂuxed for 2 h. After
the reaction was complete (TLC), the reaction mixture was ﬁltered
and the ﬁltrate was concentrated under vacuum. The residue was
triturated with hexane and the resulting solid was dried.
3. General procedure for the synthesis of 1,2,4-oxadiazolyl
dipeptides 3
To a stirred solution of amidoxime 1 (2 mmol) in ethanol was
added N-protected amino acyl ﬂuoride (3 mmol) followed by
NMM (5 mmol) at rt. After 10 min, NaOAc (2 mmol) was added
and the reaction mixture was reﬂuxed for 3 h. After completion
of the reaction (TLC), ethanol was evaporated and the residue
was suspended between ethyl acetate (15 mL) and water
(10 mL). The organic layer was washed with 10% sodium carbonate
solution (10 mL), water (15 mL  2) and brine (15 mL). The organic
layer was concentrated and the resulting crude compound was
puriﬁed by column chromatography (silica gel 100–200 mesh,
20% ethyl acetate in hexane).
4. Spectral data for selected compounds
Compound 3a: Solid; 1H NMR (300 MHz, CDCl3): d 0.95 (m, 12
H), 1.32 (s, 9H), 1.65 (m, 3H), 2.45 (m, 1H), 4.53 (m, 2H), 5.41 (s,1.Pd/C/H2
2. Z-Xaa-F,
NMM
Boc -NH
N
N O
HN-Xaa-Z
9
9a: Xaa=Ile (73%)
9b: Xaa=Gly (76%)
5.
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21.9, 24.1, 31.2, 34.3, 51.3, 63.2, 69.3, 82.5, 127.1, 128.4, 128.8,
142.1, 155.3, 155.9, 156.6, 171.2, 175.5; HRMS calcd for
C24H36N4NaO5: 483.2583, found 483.2579 [M+Na]; IR: 1701,
1697, 1657, 1634 cm1.
Compound 3c: White solid; 1H NMR (300 MHz, CDCl3): d 0.97
(m, 6H), 1.31 (s, 9H), 1.63 (m, 2H), 2.1 (m, 1H), 4.18 (s, 2H), 4.3
(m, 3H), 5.2 (m, 2H), 7.1–7.68 (m, 5H); 13C NMR (100 MHz, CDCl3):
d 16.4, 18.1, 23.1, 24.3, 31.1, 32.1, 45.8, 56.7, 62.8, 127.1, 127.9,
128.1, 128.6, 129.2, 156, 165.2, 170.1. HRMS calcd for C21H30Na-
N4O5: 441.2114, found: 441.2117 [M+Na]; IR: 1702, 1696, 1649,
1630 cm1.
Compound 3f: Off white solid; 1H NMR (300 MHz, CDCl3): d
0.93 (d, J = 6.4 Hz, 6H), 1.24 (t, J = 9.8, 3H), 1.65 (d, J = 6.8 Hz, 2H),
3.12 (m, 2H), 4.12 (d, J = 7.6 Hz, 2H), 4.23 (m, 3H), 5.1 (s, 1H),
5.32 (s, 1H), 6.9–7.7 (m, 18H); 13C NMR (100 MHz, CDCl3): d 14.6,
22.6, 25.1, 38.7, 43.7, 46.8, 50.2, 55.2, 62.0, 67.6, 120.5, 125.5,
127.5, 127.9, 128.2, 128.7, 129, 129.2, 129.7, 129.8, 135.0, 136.2,
141.8, 144.2, 156.0, 171.3, 172.0, 172.6; HRMS calcd for
C38H38N4NaO5: 653.274, found: 653.2781 [M+Na]; IR: 1712,
1696, 1652, 1640 cm1.
Compound 6a: Off white solid; 1H NMR (300 MHz, CDCl3): d
0.98 (d, J = 6.6 Hz, 3H), 1.37 (d, J = 6.8 Hz, 6H), 1.81 (m, 3H), 3.9
(m, 3H), 4.2–4.43 (m, 5H), 4.52 (m, 2H), 5.32 (m, 2H), 6.1 (br,
4H), 7.2–8.1 (m, 18 H); 13C NMR (100 MHz, CDCl3): d 16.8, 17.0,
31.5, 36.8, 45.1, 48.1, 50.3, 56.1, 63.4, 65.1, 68.7, 125.0, 126.8,
127.7, 127.9, 128.0, 128.2, 128.3, 128.7, 128.9, 129.6, 138.4,
141.0, 142.2, 144.6, 156.5, 156.9, 163.4, 172.4, 173.0, 176.1; HRMS
calcd for C42H46N6NaO8: 785.3275, found: 785.3281 [M+Na]; IR:
1708, 1698, 1666, 1634 cm1.
Compound 6b: White solid; 1H NMR (300 MHz, CDCl3): d 0.91
(d, J = 6.8 Hz, 6H), 1.02 (d, J = 5.8 Hz, 3H), 1.2 (m, 2H), 1.34 (s,
9H), 2.31 (m, 3H), 4.25 (s, 2H), 4.4–4.53 (m, 5H), 5.2 (br, 2H), 5.5
(m, 2H), 7.1–7.9 (m, 10H); 13C NMR (100 MHz, CDCl3): d 14.9,
18.3, 22.9, 27.0, 36.0, 39.3, 42.1, 53.0, 56.0, 61.1, 65.3, 68.6,
121.1, 124.2, 125.3, 125.8, 129.3, 129.9, 131.1, 132.3, 134.5,
149.0, 151.2, 156.0, 160.0, 169.0, 172.5; HRMS calcd for
C33H44N6NaO7: 659.3169, found: 659.3172 [M+Na]; IR: 1712,
1696, 1652, 1640 cm1.
Compound 7a: Solid; 1H NMR (300 MHz, CDCl3): d 0.93–0.96
(m, 12H), 1.41 (s, 9H), 1.68 (m, 2H), 2.31 (m, 2H), 3.7 (t,
J = 8.1 Hz, 2H), 4.13 (m, 2H), 5.54 (m, 2H), 5.87 (br, 2H), 7.2–7.41
(m, 5H); 13C NMR (100 MHz, CDCl3): d 18.2, 19.6, 22.5, 23.1, 29.0,
33.2, 46.5, 53.1, 67.0, 80.0, 129.2, 129.8, 135.0, 136.0, 156.0,
158.5, 171.0, 176.0; HRMS calcd for C24H38N4NaO6: 501.2689,
found 501.2684 [M+Na]; IR: 1741, 1709, 1690, 1640 cm1.
Compound 7c: Solid; 1H NMR (300 MHz, CDCl3): d 0.98 (d,
J = 6.6 Hz, 3H), 1.86 (d, J = 4.3, 2H), 3.9 (t, J = 7.8 Hz, 1H), 4.2–4.43
(m, 4H), 4.52 (m, 2H), 5.32 (m, 2H), 6.1 (br, 2H), 7.2–8.1 (m, 18
H); 13C NMR (100 MHz, CDCl3): d 16.9, 21.2, 33.2, 37.3, 39.2,
42.4, 56.1, 121.0, 122.2, 124.5, 125.3, 126.0, 128.2, 128.3, 128.6,
129.4, 129.6, 131.2, 131.5, 135.0, 142.0, 156.0, 169.5, 172.4; HRMS
calcd for C35H34N4NaO6: 629.2376, found: 629.2371 [M+Na]; IR:
1747, 1714, 1690, 1634 cm1.
Compound 8a: White solid; 1H NMR (300 MHz, CDCl3): d 0.91–
0.95 (m, 12H), 1.33 (s, 9H), 1.58–1.62 (m, 2H), 2.41 (m, 4H), 3.81–
3.92 (m, 3H), 4.18 (s, 2H), 5.45–5.6 (m, 3H), 6.9–7.4 (m, 10H); 13C
NMR (100 MHz, CDCl3): d 17.9, 19.5, 20.0, 21.0, 24.2, 28.4, 33.0,
37.1, 38.0, 44.9, 59.0, 66.5, 67.0, 122.0, 124.0, 128.5, 128.7, 129.3,
129.7, 130.0, 131.0, 157.0, 169.1, 169.7 170.0, 171.0; HRMS calcd
for C33H45N5NaO6: 630.3268, found: 630.3271 [M+Na]; IR: 1696,
1645, 1634 cm1.Compound 9b: Solid; 1H NMR (300 MHz, CDCl3): d 0.89–0.93
(m, 12H), 1.39 (s, 9H), 1.71 (m, 2H), 2.53 (m, 2H), 3.9 (m, 4H), 4.3
(s, 2H), 5.42 (m, 3H), 7.1–7.4 (m, 5H); 13C NMR (100 MHz, CDCl3):
d 18.1, 19.4, 21.0, 23.2, 24.7, 32.0, 43.2, 47.0, 56.0, 59.0, 61.0, 77.0,
128.1, 128.7, 129.0, 129.5, 129.8, 154.0, 167.1, 167.8, 169.0, 171.1;
HRMS calcd for C26H39N5NaO6: 540.2798, found: 540.2792
[M+Na]; IR: 1693, 1642, 1638 cm1.
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